Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with lung cancer.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-08-21 DOI:10.5937/jomb0-50852

Ping Wang, Mingjie Yu

{"title":"Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with lung cancer.","authors":"Ping Wang, Mingjie Yu","doi":"10.5937/jomb0-50852","DOIUrl":null,"url":null,"abstract":"Background: Primary lung cancer is one of the most prevalent malignant tumours in China. Small cell lung cancer (SCLC) is a highly malignant, undifferentiated tumour prone to metastasis and is usually diagnosed in its middle or late stages. Pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) tumour markers are recommended in the literature for early diagnosis. Objective: The purpose of this research is to probe the diagnostic value and therapeutic efficacy of serum levels of ProGRP and NSE in SCLC to enhance the level of clinical diagnosis.Methods: A total of 84 SCLC patients who were admitted to our hospital from December 2022 to March 2024 were included in the SCLC group. The NSCLC group consisted of 45 patients diagnosed with NSCLC, while the benign lung disease group consisted of 57 patients diagnosed with non-cancerous lung conditions. Furthermore, the healthy control group comprised 60 healthy individuals. The serum levels of ProGRP and NSE were compared across all four groups.Results: The SCLC group exhibited considerably elevated serum ProGRP and NSE levels compared to the healthy control group, benign lung disease group, and NSCLC group (P< 0.05). ProGRP and NSE values were higher in limited-stage SCLC than in extensive-stage SCLC (P < 0.05). The ROC curve displayed that the critical value of ProGRP for diagnosing SCLC was 136.49 pg/mL, the area under the curve (AUC) was 0.869, the sensitivity attained 80.00%, and the specificity reached 84.87%, indicating a better diagnostic efficacy than that of NSE (P< 0.05).Conclusions: The tumour markers ProGRP and NSE levels are of paramount significance for the clinical diagnosis and staging of SCLC patients. ProGRP is a more specific and sensitive tumour marker for SCLC than NSE and can be employed as an auxiliary diagnostic tool for SCLC. Thus, it is worth promoting ProGRP in a clinical setting.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"945-954"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-50852","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Primary lung cancer is one of the most prevalent malignant tumours in China. Small cell lung cancer (SCLC) is a highly malignant, undifferentiated tumour prone to metastasis and is usually diagnosed in its middle or late stages. Pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) tumour markers are recommended in the literature for early diagnosis. Objective: The purpose of this research is to probe the diagnostic value and therapeutic efficacy of serum levels of ProGRP and NSE in SCLC to enhance the level of clinical diagnosis.

Methods: A total of 84 SCLC patients who were admitted to our hospital from December 2022 to March 2024 were included in the SCLC group. The NSCLC group consisted of 45 patients diagnosed with NSCLC, while the benign lung disease group consisted of 57 patients diagnosed with non-cancerous lung conditions. Furthermore, the healthy control group comprised 60 healthy individuals. The serum levels of ProGRP and NSE were compared across all four groups.

Results: The SCLC group exhibited considerably elevated serum ProGRP and NSE levels compared to the healthy control group, benign lung disease group, and NSCLC group (P< 0.05). ProGRP and NSE values were higher in limited-stage SCLC than in extensive-stage SCLC (P < 0.05). The ROC curve displayed that the critical value of ProGRP for diagnosing SCLC was 136.49 pg/mL, the area under the curve (AUC) was 0.869, the sensitivity attained 80.00%, and the specificity reached 84.87%, indicating a better diagnostic efficacy than that of NSE (P< 0.05).

Conclusions: The tumour markers ProGRP and NSE levels are of paramount significance for the clinical diagnosis and staging of SCLC patients. ProGRP is a more specific and sensitive tumour marker for SCLC than NSE and can be employed as an auxiliary diagnostic tool for SCLC. Thus, it is worth promoting ProGRP in a clinical setting.

Abstract Image

查看原文本刊更多论文

肺癌患者血清胃泌素释放肽前体（ProGRP）和神经元特异性烯醇化酶（NSE）水平的诊断价值和治疗效果。

背景：原发性肺癌是中国最常见的恶性肿瘤之一。小细胞肺癌（SCLC）是一种高度恶性、易转移的未分化肿瘤，通常在中晚期诊断。前胃泌素释放肽前体（ProGRP）和神经元特异性烯醇化酶（NSE）肿瘤标志物在文献中被推荐用于早期诊断。目的：探讨血清ProGRP和NSE水平对SCLC的诊断价值和治疗效果，以提高临床诊断水平。方法：将2022年12月至2024年3月我院收治的84例SCLC患者纳入SCLC组。非小细胞肺癌组由45名确诊为非小细胞肺癌的患者组成，而良性肺病组由57名确诊为非癌性肺病的患者组成。此外，健康对照组由60名健康个体组成。比较四组患者血清ProGRP和NSE水平。结果：SCLC组血清ProGRP和NSE水平明显高于健康对照组、良性肺疾病组和NSCLC组（P< 0.05）。有限期SCLC的ProGRP和NSE值高于广泛期SCLC （P < 0.05）。ROC曲线显示ProGRP诊断SCLC的临界值为136.49 pg/mL，曲线下面积（AUC）为0.869，敏感性达80.00%，特异性达84.87%，诊断效果优于NSE （P< 0.05）。结论：肿瘤标志物ProGRP和NSE水平对SCLC患者的临床诊断和分期具有重要意义。ProGRP是SCLC比NSE更特异、更敏感的肿瘤标志物，可作为SCLC的辅助诊断工具。因此，在临床环境中推广ProGRP是值得的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.